FDA proposes guidance on endpoints for multiple myeloma therapeutics accelerated approval trials
Regulatory NewsFerdous Al-Faruque
Biologics/ biosimilars/ vaccinesGuidancePharmaceuticalsRegulatory Intelligence/PolicyUnited StatesUS Food and Drug Administration (FDA)